Orthofix Medical/$OFIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Orthofix Medical
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Ticker
$OFIX
Sector
Primary listing
Employees
1,616
Headquarters
Website
Orthofix Medical Metrics
BasicAdvanced
$589M
-
-$3.18
0.82
-
Price and volume
Market cap
$589M
Beta
0.82
52-week high
$20.48
52-week low
$10.24
Average daily volume
484K
Financial strength
Current ratio
2.668
Quick ratio
1.315
Long term debt to equity
43.83
Total debt to equity
38.244
Interest coverage (TTM)
-3.31%
Profitability
EBITDA (TTM)
15.984
Gross margin (TTM)
68.88%
Net profit margin (TTM)
-15.29%
Operating margin (TTM)
-10.11%
Effective tax rate (TTM)
-0.82%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-6.87%
Return on equity (TTM)
-24.63%
Valuation
Price to revenue (TTM)
0.717
Price to book
1.28
Price to tangible book (TTM)
3.19
Price to free cash flow (TTM)
1,257.909
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.012
Growth
Revenue change (TTM)
4.84%
Earnings per share change (TTM)
-1.03%
3-year revenue growth (CAGR)
20.54%
10-year revenue growth (CAGR)
7.51%
3-year earnings per share growth (CAGR)
19.50%
10-year earnings per share growth (CAGR)
19.31%
What the Analysts think about Orthofix Medical
Analyst ratings (Buy, Hold, Sell) for Orthofix Medical stock.
Bulls say / Bears say
Orthofix delivered first quarter 2025 pro forma net sales of $189.2 million, up 4.3% year-over-year, driven by 11% constant-currency growth in Global Orthopedics and a 200 basis-point expansion in adjusted EBITDA margin (Business Wire).
The TrueLok Elevate Transverse Bone Transport System received FDA 510(k) clearance and CE Mark in March 2025, marking Orthofix’s first dedicated TBT device and opening access to an estimated $1.2 billion diabetic wound market (Business Wire).
Wall Street consensus remains constructive, with analysts on average rating OFIX a “buy” and a median 12-month price target of $24, implying roughly 77% upside from recent levels (Reuters.)
Although reported net sales increased, Orthofix widened its net loss to $53.1 million, or $1.35 per share, in Q1 2025, underscoring persistent profitability challenges amid ongoing investments in growth initiatives (Business Wire).
In May 2025, Orthofix reduced its full-year 2025 net sales guidance to $808 million–$816 million from the prior range of $818 million–$826 million, reflecting short-term headwinds from targeted commercial transitions and NGO impacts (Business Wire).
In March 2025, Kuehn Law initiated an investigation into Orthofix, alleging that certain officers and directors may have breached their fiduciary duties by misrepresenting management conduct, exposing the company to potential litigation and reputational risk (GlobeNewswire.)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Orthofix Medical Financial Performance
Revenues and expenses
Orthofix Medical Earnings Performance
Company profitability
Orthofix Medical News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Orthofix Medical stock?
Orthofix Medical (OFIX) has a market cap of $589M as of September 15, 2025.
What is the P/E ratio for Orthofix Medical stock?
The price to earnings (P/E) ratio for Orthofix Medical (OFIX) stock is 0 as of September 15, 2025.
Does Orthofix Medical stock pay dividends?
No, Orthofix Medical (OFIX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Orthofix Medical dividend payment date?
Orthofix Medical (OFIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Orthofix Medical?
Orthofix Medical (OFIX) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.